Page 1 of 62

# **Summary Table of Study Protocol**

Title	POWER: Real World Data of 1st line Panitumumab Treatment in Combination With Chemotherapy in non Resectable Wild Type (WT) RAS Metastatic Colorectal Cancer (mCRC) Subjects in Austria, Bulgaria, Croatia, Czech Republic, Hungary, Poland, Slovenia, Romania, Russia an Observational Ambidirectional Study
Protocol version identifier	20170734, Version 1.0
Date of last version of the protocol	N/A
EU Post Authorization Study (PAS) Register No	N/A
Active Substance	Panitumumab
Medicinal Product	Panitumumab (Vectibix®)
Product Reference	EMEA/H/C/000741
Joint PASS	No
Research Question and Objectives	To obtain characteristics of subjects with WT <i>RAS</i> non resectable mCRC receiving panitumumab in combination with chemotherapy as a 1 <sup>st</sup> line treatment, and to describe the patterns of treatment, including 1 <sup>st</sup> and 2 <sup>nd</sup> line therapies.
Countries of Study	Austria, Bulgaria, Croatia, Czech Republic, Hungary, Poland, Slovenia, Romania, Russia
Author	Therapeutic Area Head Oncology/Hematology, Europe North East - Medical Amgen (Europe) GmbH, Suurstoffi 22, CH-6343 Rotkreuz

# **Marketing Authorization Holder**

Marketing authorization holder(s)	Amgen Europe B.V.
MAH Contact	Amgen Europe B.V. Minervum 7061 NL-4817 ZK Breda The Netherlands



Date: 08 August 2018 Page 2 of 62

## **Confidentiality Notice**

This document contains confidential information of Amgen Inc.

This document must not be disclosed to anyone other than the site study staff and members of the Institutional Review Board/Independent Ethics Committee/Institutional Scientific Review Board or equivalent, as applicable.

The information in this document cannot be used for any purpose other than the evaluation or conduct of the research without the prior written consent of Amgen Inc.

If you have questions regarding how this document may be used or shared, call the Amgen Medical Information number:

Amgen's general number in the UK +44 (0) 1895 525000 or +44 (0) 800 243104.



Name of Coordinating Investigator

Date: 08 August 2018 Page 3 of 62

## **Investigator's Agreement**

I have read the attached protocol entitled "POWER: Real World Data of 1st line panitumumab treatment in combination with chemotherapy in non resectable WT *RAS* metastatic colorectal cancer (mCRC) subjects in Austria, Bulgaria, Croatia, Czech Republic, Hungary, Poland, Slovenia, Romania, Russia an Observational Ambidirectional Study", dated *08 August 2018* and agree to abide by all provisions set forth therein.

used for any purpose other than the evaluation or conduct of the clinical investigation			
without the prior written consent of Amgen Inc.			
Signature			

Date (DD Month YYYY)

I agree to ensure that the confidential information contained in this document will not be



Page 4 of 62

Date: 08 August 2018

Figure 1. Study Design Schema Safety **Prospective Observation Period Retrospective Period** Follow-(12-1 months) (15 months) up (30 days) Baseline: signature and Enrolment Observation Start of 1st line Study chemotherapy & ð panitumumab 12-1 months End of prior to <u>S</u> End **Enrolment** Continuous 1<sup>st</sup> line treatment administration Safety Follow-up If progression and start of 2<sup>nd</sup> line treatment, Continuous 1<sup>st</sup> line treatment Safety Follow-up administration a patient goes directly to Safety Follow-up Observation Period after the end of 1st line **End** Continuous 1st line treatment treatment without subsequent 2<sup>nd</sup> line treatment: of

up to 15 months



studv

administration

## 1. Table of Contents

Sur	nmary <sup>-</sup>	Table of S	Study Protoco	ol	1
1.	Table of Contents			5	
2.	List of Abbreviations and Terms			8	
3.	Responsible Parties				
4.	Abstract				
5.	Amei	ndments a	and Updates		15
6.	Milestones				16
7. Rati		ationale and Background			16
	7.1	Disease	es and Thera	apeutic Area	16
	7.2	Rationa	ale		20
	7.3	Statistic	cal Inference	e (Estimation or Hypothesis[es])	21
8.	Rese	arch Que	stion and Ol	ojectives	21
	8.1				
	8.2	,	•	/es	
	8.3			ves (if available)	
9.	Rese	search Methods			22
	9.1				
	9.2			Population	
		9.2.1	•	riod	
		9.2.2	•	and Number of Sites	
		9.2.3	Subject/H	lealthcare Professional Eligibility	26
			9.2.3.1	Inclusion Criteria	26
			9.2.3.2	Exclusion Criteria	27
		9.2.4	Matching		27
		9.2.5		Retrospective Data Collection and nt Visit	
		9.2.6		ve Observation Period	
		9.2.7	-	bservation Visit	
		9.2.8		ollow-up	
		9.2.9	,	udy Visit	
	9.3				
		9.3.1	Exposure	Assessment	31
		9.3.2	Outcome	Assessment	32
		9.3.3	Covariate	Assessment	33
		9.3.4	Validity a	nd Reliability	33
	9.4	Data So	ources		34
	9.5	Study S	Study Size3		



	9.6	Data Ma	anagement.		34
		9.6.1	Obtaining	Data Files	35
		9.6.2	Linking D	ata Files	36
		9.6.3	Review a	nd Verification of Data Quality	36
	9.7	Data Ar			
		9.7.1	Planned	Analyses	36
			9.7.1.1	Interim Analysis/Analyses	36
			9.7.1.2	Primary Analysis	
			9.7.1.3	Final Analysis	36
		9.7.2	Planned I	Method of Analysis	37
			9.7.2.1	General Considerations	37
			9.7.2.2	Missing or Incomplete Data and Lost to Follow-up	37
			9.7.2.3	Descriptive Analysis	
			9.7.2.4	Analysis of the Primary, Secondary and Exploratory Outcomes	
			9.7.2.5	Sensitivity Analysis	
		9.7.3	Analysis	of Safety Outcomes	39
	9.8	Quality	Control		40
	9.9	Limitations of the Research Methods			40
		9.9.1	Internal V	/alidity of Study Design	40
			9.9.1.1	Selection Bias	40
			9.9.1.2	Confounding	41
		9.9.2	External '	Validity of Study Design	41
		9.9.3	Analysis	Limitations	41
		9.9.4	Limitatior Data	ns Due to Missing Data and/or Incomplete	41
10.	Protection of Human Subjects			41	
10.			-		41
	10.2			Committee (IEC)	
	10.3	-		ılity	
	10.4	•		o Withdraw	
11.				Reporting of Safety Information and Product	4.0
	-			<b>-</b>	
	11.1		•	Events	
		11.1.1		Events	
		11.1.2		Adverse Events	
		11.1.3		fety Findings	
	44.0	11.1.4		Complaints	44
	11.2	Require	ments	Recording and Submission to Amgen	
		11 2 1	Prospecti	ive Observational Period	45



		11.2.2 S	afety Reporting Requirement to Regulatory Bodies	46	
12.	12. Administrative and Legal Obligations46				
	12.1		nendments and Study Termination		
13.	13. Plans for Disseminating and Communicating Study Results46				
	13.1	Publication	Policy	47	
14.	Refere	nces		48	
15.	Appen	dices		51	
			List of Tables		
Table	e 1. Pla	nned Milest	ones for the POWER Study	16	
Tabl	Table 2. Objectives and Outcomes24			24	
			List of Figures		
Figu	re 1. St	udy Design	Schema	4	
			List of Appendices		
Арре	endix A.	List of Star	d-alone Documents	52	
Арре	Appendix B. Sample Safety Reporting Form(s)53				
Appe	Appendix C. Pregnancy and Lactation Notification Worksheets58				
Арре	endix D.	Additional	Safety Reporting Information	60	
Appe	endix E.	Schedule o	f Assessments	61	
Appe	endix F.	Functional	Assessment of Cancer Therapy-EGFRI-18	62	

Date: 08 August 2018 Page 8 of 62

## 2. List of Abbreviations and Terms

Abbreviation or Term	Definition/Explanation	
ADR	adverse drug reaction	
AE	adverse event	
BRAF	B-Raf proto-oncogene serine/threonine kinase, gene of <i>RAF</i> family	
CA 19-9	cancer antigen 19-9	
CapeOX	capecitabine/oxaliplatin	
CEA	carcinoembryonic antigen	
CEE	central and eastern Europe	
CI	confidence Intervals	
COPD	chronic obstructive pulmonary disease	
CRC	colorectal cancer	
CT	computer tomography	
DpR	depth of response	
ECOG	eastern cooperative oncology group	
eCRF	electronic case report form	
EDC	electronic data capture	
EGF	epidermal growth factor	
EGFR	epidermal growth factor receptor	
EGFRI	epidermal growth factor receptor inhibitor	
EHR	electronic health records	
ETS	early tumour shrinkage	
FACT	functional assessment of cancer therapy	
FOLFIRI	FOL (folinic acid, leucovorin,LV) F (fluorouracil,5FU) IRI (irinotecan)	
FOLFOX	FOL (folinic acid) F (5FU) OX (oxaliplatin)	
FOLFOXIRI	FOL (folinic acid) F (5FU) OX (oxaliplatin) IRI (irinotecan)	
ICF	informed consent form	
ICJME	international committee of medical journal editors	
IEC	independent ethics committee	
Ig	Immunoglobulin	
IRB	institutional review board	
IROX	IR (irinotecan) OX (oxaliplatin)	
IVRS	interactive voice response system	
KRAS	Kirsten rat sarkoma 2 viral oncogene homolog, gen of RAS family	



Product: Panitumumab (Vectibix®)
Protocol Number: 20170734 POWER
Date: 08 August 2018

re: 08 August 2018 Page 9 of 62

Abbreviation or Term	Definition/Explanation	
LV	Leucovorin, folinic acid	
mCRC	metastatic colorectal cancer	
MedDRA	Medical dictionary for regulatory activities	
MRI	magnetic resonance imaging	
NRAS	neuroblastoma RAS viral oncogene homolog, gene of RAS family	
ORR	objective response rate	
OS	overall survival	
OTC	over the counter	
PET	positron emission tomography	
PFS	progression-free survival	
PP	percentage points	
QoL	quality of life	
RECIST	response evaluation criteria in solid tumours	
RR	response rate	
SAP	statistical analysis plan	
SmPC	summary of product characteristics	
TGFα	transforming growth factor-alpha	
TNM	tumour node metastasis	
WT	wild type	
VEGF	vascular endothelial growth factor	
VEGFR	vascular endothelial growth factor receptor	
5-FU	fluorouracil	
Baseline Visit	The date of start of 1st line chemotherapy and panitumumab	
Enrolment Visit	The date of informed consent signature	
End of Observation Visit	The visit at the end of Prospective Observation Period or the last visit before death or withdrawal of informed consent or lost to follow-up	
End of Study Visit	The visit at the end of Safety Follow-up or at the end of Prospective Observation Period if panitumumab was not administered in the last 4 weeks of observation	
Prospective Observation Period	Period between Enrolment and start of Safety Follow-up defined as 1) 15 months of continuous 1 <sup>st</sup> line panitumumab plus chemotherapy treatment administration or 2) up to 15 months after stop of 1 <sup>st</sup> line treatment without subsequent 2 <sup>nd</sup> line treatment or 3) 1 <sup>st</sup> line panitumumab plus chemotherapy until progression/start of 2 <sup>nd</sup> line treatment or death or withdrawal of informed consent or loss-to follow-up, whichever occurs first	



Product: Panitumumab (Vectibix®) Protocol Number: 20170734 POWER Date: 08 August 2018

Date: 08 August 2018 Page 10 of 62

Abbreviation or Term	Definition/Explanation
Retrospective Period	Period between start of 1 <sup>st</sup> line panitumumab plus chemotherapy and enrolment
Safety Follow-up (SFU)	30 days of follow-up after Prospective Observation Period for subjects who reached 15 months of 1 <sup>st</sup> line panitumumab plus chemotherapy if panitumumab was administered in the last 4 weeks of observation or for subjects who started 2 <sup>nd</sup> line treatment. Safety Follow-up period does not apply to subjects who completed 15 months of observation consisting of shortened 1 <sup>st</sup> line treatment without subsequent 2 <sup>nd</sup> line treatment (as described under #2 in the definition of Prospective Observation Period).



Product: Panitumumab (Vectibix®) Protocol Number: 20170734 POWER Date: 08 August 2018

Date: 08 August 2018 Page 11 of 62

## 3. Responsible Parties

Clinical Study Sponsor:	Amgen Ltd. 240 Cambridge Science Park, Milton Road, Cambridge, UK
Key Sponsor contacts:	Therapeutic Area Head Oncology/Haematology, Europe North East - Medical Amgen (Europe) GmbH Suurstoffi 22, CH-6343 Rotkreuz Switzerland



Date: 08 August 2018 Page 12 of 62

#### 4. Abstract

#### Study Title

POWER: Real World Data of 1<sup>st</sup> line panitumumab treatment in combination with chemotherapy in non resectable wild type *RAS* metastatic colorectal cancer (mCRC) subjects in Austria, Bulgaria, Croatia, Czech Republic, Hungary, Poland, Slovenia, Romania, Russia an Observational Ambidirectional Study

### Study Background and Rationale

Colorectal cancer (CRC) is the fourth most common cause of cancer mortality worldwide and the second most common cancer in Europe. Even up to 50% of all CRC subjects eventually develop metastatic disease. The predominant treatments for metastatic CRC (mCRC) are surgery and chemotherapy. In a number of cases, conventional agents alone are not adequate and targeted agents, including biologics, are necessary.

Panitumumab, an antibody against human epidermal growth factor receptor (EGFR), has been shown to be effective in mCRC and was first approved in the European Union in 2007 for the indication of adults with mCRC with non-mutated *RAS* gene. It was also approved as a 1<sup>st</sup> line agent in combination with FOLFOX (folinic acid/5-flourouracil/oxaliplatin) and launched in the selected European countries in 2015-2018.

Clinical studies with panitumumab revealed improvements of progression-free survival (PFS) and overall survival (OS) connected with early tumour shrinkage (ETS) in subjects with wild type (WT) *RAS* mCRC. However, these and other studies failed to collect enough information to assess the effect of right- and left-side colon cancer and their interactive responsiveness EGFR inhibition. In addition, more data is needed to assess the safety effects of injectable anti-EGFR agents, mainly skin toxicity that occurs in about 60—90% of subjects.

This study will address the question of the use of panitumumab as 1<sup>st</sup> line treatment in daily clinical practice in the selected European countries, especially with recent launch of the therapy. The study will also provide insight into the choice of 2<sup>nd</sup> line treatment regimen after disease progression from 1<sup>st</sup> line panitumumab plus chemotherapy. Further data will be collected to better understand the impact and management of skin toxicity. The real world data will be explored not just in terms of the long-term therapy optimization, but also in terms of the impact of chosen therapies on quality of life and health economic indicators.



Date: 08 August 2018 Page 13 of 62

### Research Question and Objective(s)

Primary Objective(s)

To obtain characteristics of subjects with WT *RAS* non resectable mCRC receiving panitumumab in combination with chemotherapy as a 1<sup>st</sup> line treatment, and to describe the patterns of treatment, including 1<sup>st</sup> and 2<sup>nd</sup> line therapies.

- Secondary Objective(s)
  - To assess the response to 1<sup>st</sup> line treatment.
  - To explore the relationship between Death and/or Disease Progression and subject / country characteristics.
  - To characterize the group of subjects with ETS outcome (if available).
  - To assess incidence of adverse drug reactions (ADR).
- Hypothesis(es)/Estimation

This study will be observational; no hypothesis will be carried out.

### Study Design/Type

This is a multicentre, ambidirectional (retrospective-prospective), observational study in the selected European countries.

#### Study Population or Data Resource

The study population will consist of subjects (≥18 years old) with initially non resectable WT *RAS* mCRC receiving panitumumab in combination with chemotherapy as 1<sup>st</sup> line treatment. The observations will be conducted in the selected European countries, including but not limited to Austria, Bulgaria, Croatia, Czech Republic, Hungary, Poland, Slovenia, Romania and Russia. Study period will last 12 months of enrolment plus max.16 months of observation (min. 1 month of retrospective plus max. 15 months of prospective observation), plus 30 days of Safety Follow-up.

### **Summary of Subject Eligibility Criteria**

#### **Inclusion Criteria**

- Subject who received first infusion of panitumumab in combination with chemotherapy as 1<sup>st</sup> line treatment between 1 and 12 months before enrolment and who continues treatment with panitumumab in combination with chemotherapy at the time of enrolment
- Subject with a record of WT RAS CRC diagnosis as per standard clinical practice
- Subject with metastatic carcinoma of the colon or rectum with at least one metastatic site recorded
- Subject with initially non resectable mCRC at the start of panitumumab plus chemotherapy treatment



Date: 08 August 2018 Page 14 of 62

 Subject who was diagnosed with a tumour, assessed by CT/MRI etc. prior to panitumumab plus chemotherapy initiation

- Histologically or cytologically confirmed carcinoma of the colon or rectum as the primary site
- Subject ≥ 18 years of age on the date of enrolment
- Subjects whose care will be managed primarily by the enrolling physician and/ or all records will be available from initiation of 1st line panitumumab plus chemotherapy treatment to end of safety follow up
- Subject or subject's legally acceptable representative has provided informed consent if applicable per local regulations

#### **Exclusion Criteria**

- Subject with proven brain metastasis
- Subject with mCRC as a secondary malignancy
- Ongoing or planned concurrent participation in any interventional clinical trial

### Safety Follow-up

Safety Follow-up will last approximately 30 days after the start of 2<sup>nd</sup> line treatment, or after 15 months of observation if panitumumab was administered in the last 4 weeks of observation, whichever occurs first, except for death, withdrawal of consent or lost to follow-up. Relevant AE's will be reported during this time.

#### **Variables**

Outcome Variable(s)

The primary outcome variables will contain demographics criteria, targeted medical history and the current status of disease, including dose, infusion schedule, and changes in 1<sup>st</sup> and 2<sup>nd</sup> line treatments.

Key secondary outcomes will include Death, Disease progression, response rate (RR), rate of conversion to resectable mCRC, tumour markers, ETS (if available) and ADR incidents. The relationship between Death, Disease Progression, ETS (if available), and subject characteristics with the particular interest in tumour location will be assessed.

The optional exploratory outcomes to be assessed will include type of proactive and reactive measures of skin toxicity and type of treatment applied. Biomarkers status will be evaluated if possible.



Date: 08 August 2018 Page 15 of 62

Exposure Variable(s)

The main exposure variables will be the country, location of tumour (left vs. right side), current disease status and treatment regimen.

Other Covariate(s)

The potential influence of demographic covariates such as body weight, sex and age and covariates related to prior therapies will be explored.

## Study Sample Size

Approximately a total of 600 subjects are planned to be enrolled at approximately 70 sites. The sample size will provide reasonable precision to statistical analysis. The size of subject population will fulfil the requirements of reimbursement agencies in the selected European countries.

The sample size of 600 would ensure that the half-width of the 95% confidence interval (CI) for the proportion of subjects reporting important outcome measures would be no larger than the 4 percentage points (p.p.) for the overall study population.

## **Data Analysis**

The analysis of this study will be descriptive in nature. The categorical data obtained in the study will be examined with regards to precision rather than statistical power. Proportions and confidence intervals will be most useful if reported in subgroups rather than overall. The data will be summarized for the total study population and per country. Primary outcomes will be summarized using descriptive statistics. Secondary outcomes will be analysed using Kaplein Meier (death, disease progression) and will be summarized descriptively. Exploratory outcomes will be summarized using descriptive statistics.

### 5. Amendments and Updates

None

